Supplementary Figure 4 from Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma

Chen Liang,Yi Qin,Bo Zhang,Shunrong Ji,Si Shi,Wenyan Xu,Jiang Liu,Jinfeng Xiang,Dingkong Liang,Qiangsheng Hu,Quanxing Ni,Jin Xu,Xianjun Yu

DOI: https://doi.org/10.1158/1541-7786.22512175.v1

2023-01-01

Abstract:FBW7 was involved in the expression and shedding of CA125

What problem does this paper attempt to address?

Supplementary Figure 3 from Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma

Liang Chen,Yi Qu,Bo Zhang,Shunrong Ji,Si Shi,Wei Xu,Jiang Liu,Jinfeng Xiang,Dingkong Liang,Qiangsheng Hu,Quanxing Ni,Jing Xu,Lei Yu

DOI: https://doi.org/10.1158/1541-7786.22512178

2023-01-01

Abstract:c-Myc overexpression increased the expression and shedding of CA125
Supplementary Figure 2 from Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma

Chen Liang,Yi Qin,Bo Zhang,Shunrong Ji,Si Shi,Wenyan Xu,Jiang Liu,Jinfeng Xiang,Dingkong Liang,Qiangsheng Hu,Quanxing Ni,Jin Xu,Xianjun Yu

DOI: https://doi.org/10.1158/1541-7786.22512181

2023-01-01

Abstract:ERK was involved in c-Myc expression in pancreatic cancer cells
Data from Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma

Chen Liang,Yi Qin,Bo Zhang,Shunrong Ji,Si Shi,Wenyan Xu,Jiang Liu,Jinfeng Xiang,Dingkong Liang,Qiangsheng Hu,Quanxing Ni,Jin Xu,Xianjun Yu

DOI: https://doi.org/10.1158/1541-7786.c.6540157

2023-01-01

Abstract:<div>AbstractPancreatic ductal adenocarcinoma (PDAC) is a devastating disease with the 5-year survival rate less than 6%. Previous results indicated that serum levels of CA125 (encoded by MUC16) could be used to predict which groups of pancreatic cancer patients may benefit from surgery. However, the underlying mechanism remains elusive. Herein, using the Cancer Genome Atlas and clinicopathologic data obtained from our center, we demonstrate that high CA125 serum levels and expression levels of MUC16 are predictive of poor prognosis. MUC16 is also validated as a downstream target of KRAS, and their expression strongly correlated with each other in vitro and in vivo. Mechanistically, the KRAS/ERK axis induced upregulation of MUC16 and shedding of CA125 via its effector c-Myc in SW1990 and PANC-1 pancreatic cancer cells. Notably, proto-oncogene c-Myc could bind to the promoter of MUC16 and transcriptionally activate its expression. Taken together, these data establish CA125 as a prognostic marker for pancreatic cancer, and mechanistic studies uncovered the KRAS/c-Myc axis as a driving factor for upregulation of MUC16.Implications: The current study uncovers the contribution of oncogenic KRAS to serum marker CA125 production through a mechanism that involves the ERK/c-Myc axis. Mol Cancer Res; 15(2); 201–12. ©2016 AACR.</div>
Supplementary Tables 1-7 from Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma

Chen Liang,Yi Qin,Bo Zhang,Shunrong Ji,Si Shi,Wenyan Xu,Jiang Liu,Jinfeng Xiang,Dingkong Liang,Qiangsheng Hu,Quanxing Ni,Jin Xu,Xianjun Yu

DOI: https://doi.org/10.1158/1541-7786.22512169

2023-01-01

Abstract:Supplementary Table S1. Primers sequences used in the real-time PCR. Supplementary Table S2. siRNA oligoes used in the study. Supplementary Table S3. Primers sequences used in the quantitative ChIP. Supplementary Table S4. Clinicopathological features and correlation of MUC16 expression in PDAC in the TCGA cohorts. Supplementary Table S5. Univariate and multivariate Cox regression of Overall survival for patients with PDAC in the TCGA cohorts. Supplementary Table S6. Clinicopathological features and correlation of MUC16 expression in PDAC in the FUSCC cohorts. Supplementary Table S7. Univariate and multivariate Cox regression of Overall survival for patients with PDAC in the FUSCC cohorts.
Supplementary Figures 1-3 from the Novel KLF4/MSI2 Signaling Pathway Regulates Growth and Metastasis of Pancreatic Cancer

Kun Guo,Jiujie Cui,Ming Quan,Dacheng Xie,Zhiliang Jia,Daoyan Wei,Liang Wang,Yong Gao,Qingyong Ma,Keping Xie

DOI: https://doi.org/10.1158/1078-0432.22462092.v1

2023-01-01

Abstract:Supplementary Figure S1. Expression of MSI2 in PDAC specimens. Supplementary Figure S2. Localization of MSI2 in PDAC cells. Supplementary Figure S3. Co-expression of MSI2 and KLF4 in colon and gastric cancer cells.
Supplementary Figure 5 from Canonical Wnt Signaling is Required for Pancreatic Carcinogenesis

Yaqing Zhang,John P. Morris,Wei Yan,Heather K. Schofield,Austin Gurney,Diane M. Simeone,Sarah E. Millar,Timothy Hoey,Matthias Hebrok,Marina Pasca di Magliano

DOI: https://doi.org/10.1158/0008-5472.22394955.v1

2023-01-01

Abstract:PDF file - 4422K, Supplemental Figure 5. Survival curve of KC and KDC mice. PDA in KC and KDC mice.
The Clinical Utility of CA125/MUC16 in Pancreatic Cancer: A Consensus of Diagnostic, Prognostic and Predictive Updates by the Chinese Study Group for Pancreatic Cancer (CSPAC)

Liang Liu,Jinfeng Xiang,Rufu Chen,Deliang Fu,Defei Hong,Jihui Hao,Yixiong Li,Jiangtao Li,Shengping Li,Yiping Mou,Gang Mai,Quanxing Ni,Li Peng,Renyi Qin,Hongang Qian,Chenghao Shao,Bei Sun,Yongwei Sun,Min Tao,Bole Tian,Hongxia Wang,Jian Wang,Liwei Wang,Wei Wang,Weilin Wang,Jun Zhang,Gang Zhao,Jun Zhou,Xianjun Yu

DOI: https://doi.org/10.3892/ijo.2015.3316

2015-01-01

International Journal of Oncology

Abstract:The prognosis for pancreatic cancer (PC) is poor; however, the timely and accurate treatment of this disease will significantly improve prognosis. Serum biomarkers involve non-invasive tests that facilitate the early detection of tumors, predict outcomes and assess responses to therapy, so that the patient can be continuously monitored and receive the most appropriate therapy. Studies have reported that cancer antigen (CA)125 [also known as mucin 16 (MUC16)] has functional significance in the tumorigenic, metastatic and drug resistant properties of PC. Our aim was to use this biomarker in the diagnosis, detection of metastasis, prognosis and in the monitoring of the treatment effects of PC. Members of the Chinese Study Group for Pancreatic Cancer (CSPAC) reviewed the literature on CA125/MUC16 and developed an objective consensus on the clinical utility of CA125/MUC16 for PC. They confirmed the role of CA125/MUC16 in tumorigenesis and the progression of PC, and recommended monitoring CA125/MUC16 levels in all aspects of the diagnosis and treatment of PC, particularly those that involve the monitoring of treatments. In addition, they suggested that the combination of other biomarkers and imaging techniques, together with CA125/MUC16, would improve the accuracy of the clinical decision-making process, thereby facilitating the optimization of treatment strategies. Periodic clinical updates of the use of CA125/MUC16 have been established, which are important for further analyses and comparisons of clinical results from affiliates and countries, particularly as regards the in-depth biological function and clinical translational research of this biomarker.
SUPPLEMENTARY figure 6 from IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma

Song Gao,Yan Sun,Xuebin Zhang,Limei Hu,Yuexin Liu,Corrine Yingxuan Chua,Lynette M. Phillips,He Ren,Jason B. Fleming,Huamin Wang,Paul J. Chiao,Jihui Hao,Wei Zhang

DOI: https://doi.org/10.1158/0008-5472.22412531.v1

2023-01-01

Abstract:Quantification of western blotting from main Figure 6 and the mRNA levels of PTEN.
Abstract A069: Study of MUC16/ERBB axis in pancreatic cancer

Amina Baniya,Michael A. (Tony) Hollingsworth

DOI: https://doi.org/10.1158/1538-7445.panca2023-a069

IF: 11.2

2024-01-18

Cancer Research

Abstract:Background: Pancreatic cancer is the third leading cause of cancer-related deaths due to its poor prognosis and highly malignant nature. The altered expression of glycans and glycoproteins is associated with malignancy. MUC16 (also known as CA125) is a member of mucin family of glycoproteins known to line epithelial cells for protection and lubrication and is overexpressed in several cancer types, including pancreatic cancer, often linked with enhanced disease progression, metastasis, and reduced patient survival. Significance: Circulating levels of MUC16/CA125 has been used as a biomarker to monitor adenocarcinoma for decades. However, the functional role of CA125/MUC16 is yet to be elucidated due to a lack of studies on its large, heavily glycosylated structure and unknown functional domains. We present evidence that in addition to serving as a biomarker, circulating MUC16 has pro-tumorigenic activities. Hypothesis: Based on recent findings, we hypothesize that isoforms of MUC16 have high avidity for ErbB receptor and integrin complexes, with concomitant activation of downstream signaling cascades that include Akt and FAK, respectively. These result in the increased tumorigenic potential of pancreatic cancer cells in an autocrine manner. Experimental Design: There are four members of ErbB receptors; where receptor dimerization is a function of ligand binding and results in distinct downstream oncogenic signaling cascades. We evaluated the binding of MUC16 to different ErbB receptors, and its capacity to activate downstream signaling pathways using pancreatic cell line models that have different combinations of knock out/down of each ErbB receptor. We evaluated the global changes in the phosphorylation of oncogenic signaling molecules due to MUC16 binding using Reverse Phase Protein Array (RPPA). Results: We found that MUC16 activates Erbb4 (Y1162) along with other members of ErbB receptor family, where glycosylation of MUC16 is crucial for its biological activity. MUC16 enhanced oncogenic signaling through the phosphorylation of various downstream molecules and activated PI3K, RTK, MAPK, and DNA repair pathways. Our future directions include elucidating the molecular mechanism by which MUC16 activates the oncogenic signaling cascades via binding to ErbB receptors using our pancreatic cell line-based models. Conclusions: Understanding the biological activity of MUC16 and its cleaved product will further help in investigating the role of MUC16 in tumor microenvironment and at distant organ sites to influence the metastatic niche. Citation Format: Amina Baniya, Michael A. (Tony) Hollingsworth. Study of MUC16/ERBB axis in pancreatic cancer [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Pancreatic Cancer; 2023 Sep 27-30; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(2 Suppl) nr A069.

oncology
SUPPLEMENTARY figure 5 from IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma

Song Gao,Yan Sun,Xuebin Zhang,Limei Hu,Yuexin Liu,Corrine Yingxuan Chua,Lynette M. Phillips,He Ren,Jason B. Fleming,Huamin Wang,Paul J. Chiao,Jihui Hao,Wei Zhang

DOI: https://doi.org/10.1158/0008-5472.22412534

2023-01-01

Abstract:Quantification of western blotting from main Figure 5.
Supplementary Figure 2 from Canonical Wnt Signaling is Required for Pancreatic Carcinogenesis

Yaqing Zhang,John P. Morris,Wei Yan,Heather K. Schofield,Austin Gurney,Diane M. Simeone,Sarah E. Millar,Timothy Hoey,Matthias Hebrok,Marina Pasca di Magliano

DOI: https://doi.org/10.1158/0008-5472.22394964.v1

2023-01-01

Abstract:PDF file - 6297K, Supplemental Figure 2. Pancreatic histology in DKK1 mice on doxy; KC and KDC mice without doxy.
Supplementary Figures 5 - 6 from HAb18G/CD147 Promotes Pstat3-Mediated Pancreatic Cancer Development Via CD44s

Ling Li,Wenhua Tang,Xiaoqing Wu,David Karnak,Xiaojie Meng,Rachel Thompson,Xinbao Hao,Yongmin Li,Xiaotan T. Qiao,Jiayuh Lin,James Fuchs,Diane M. Simeone,Zhi-Nan Chen,Theodore S. Lawrence,Liang Xu

DOI: https://doi.org/10.1158/1078-0432.22446371.v1

2023-01-01

Abstract:PDF file - 451K, Figure S5: CyPA promotes HAb18G/CD147-CD44s-pSTAT3 signaling and correlated pancreatic cell growth (related to Figure 2, 3). Figure S6: HAb18G/CD147 and CD44s are co-expressed and associated in pancreatic cancer (related to Figure 4).
Supplementary Figure 4 from HAb18G/CD147 Promotes Pstat3-Mediated Pancreatic Cancer Development Via CD44s

Ling Li,Wenhua Tang,Xiaoqing Wu,David Karnak,Xiaojie Meng,Rachel Thompson,Xinbao Hao,Yongmin Li,Xiaotan T. Qiao,Jiayuh Lin,James Fuchs,Diane M. Simeone,Zhi-Nan Chen,Theodore S. Lawrence,Liang Xu

DOI: https://doi.org/10.1158/1078-0432.22446374

2023-01-01

Abstract:PDF file - 263K, The effects of HAb18G/CD147 promoting pancreatic tumor development are confirmed with pGIPZ and pTRIPZ CD147 shRNA (related to Figure 1).
SUPPLEMENTARY figure 7 from IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma

Song Gao,Yan Sun,Xuebin Zhang,Limei Hu,Yuexin Liu,Corrine Yingxuan Chua,Lynette M. Phillips,He Ren,Jason B. Fleming,Huamin Wang,Paul J. Chiao,Jihui Hao,Wei Zhang

DOI: https://doi.org/10.1158/0008-5472.22412528

2023-01-01

Abstract:Expression of IGFBP1, IGFBP3, IGFBP4, and IGFBP5 in tumors from PDAC patients and relationship of IGFBP3 and IGFBP5 expression to patient survival.
C-terminus of MUC16 Activates Wnt Signaling Pathway Through Its Interaction with Β-Catenin to Promote Tumorigenesis and Metastasis

Qi Liu,Zhen Cheng,Lianzhong Luo,Yun Yang,Zhenzhu Zhang,Huanhuan Ma,Tao Chen,Xi Huang,Shu-Yong Lin,Meijun Jin,Qinxi Li,Xiaotong Li

DOI: https://doi.org/10.18632/oncotarget.9191

2016-01-01

Oncotarget

Abstract:MUC16/CA125 has been identified as a prominent cancer biomarker, especially for epithelial ovarian cancers, in clinical test for over three decades. Due to its huge mass, limited knowledge of MUC16 was acquired previously. By utilizing a well characterized self-made MUC16 monoclonal antibody, we identified the endogenous interaction between a C-terminal fragment of MUC16 (MUC16C) and β-catenin for the first time, and further elucidated that trans-activation domain of β-catenin is required for this interaction. Such interaction could activate the Wnt/β-catenin signaling pathway by facilitating cytosol-nucleus transportation of β-catenin, consequently induce cell proliferation and the migration, eventually lead to tumorigenesis and metastasis in nude mice. Consistently, knockdown of MUC16 significantly weakened the capabilities of cells for proliferation and migration. Based on our discovery, we suggest that MUC16 appears as an attractive target for the development of effective anticancer drugs.
Supplementary Figure.3 from the Tautomerase Activity of Tumor Exosomal MIF Promotes Pancreatic Cancer Progression by Modulating MDSC Differentiation

Xuebing Jia,Jianbei Xi,Binle Tian,Yuanyuan Zhang,Zhilong Wang,Fan Wang,Zheng Li,Jiang Long,JianFei Wang,Guo-Huang Fan,Qi Li

DOI: https://doi.org/10.1158/2326-6066.24935269.v1

2024-01-01

Abstract:High expression of MIF in pancreatic cancer is associated with poor survival.
Supplementary Figure S1-S18 from A PLCB1–PI3K–AKT Signaling Axis Activates EMT to Promote Cholangiocarcinoma Progression

Shuhang Liang,Hongrui Guo,Kun Ma,Xianying Li,Dehai Wu,Yiqi Wang,Wei Wang,Shugeng Zhang,Yifeng Cui,Yufeng Liu,Linmao Sun,Bo Zhang,Mengyang Xin,Ning Zhang,Huanran Zhou,Yao Liu,Jiabei Wang,Lianxin Liu

DOI: https://doi.org/10.1158/0008-5472.22561916

2023-01-01

Abstract:Supplementary Figure S1-S18
Supplementary Figure.5 from the Tautomerase Activity of Tumor Exosomal MIF Promotes Pancreatic Cancer Progression by Modulating MDSC Differentiation

Xuebing Jia,Jianbei Xi,Binle Tian,Yuanyuan Zhang,Zhilong Wang,Fan Wang,Zheng Li,Jiang Long,JianFei Wang,Guo-Huang Fan,Qi Li

DOI: https://doi.org/10.1158/2326-6066.24935263

2024-01-01

Abstract:Effects of IPG1576 on the appearance of the spleen and the splenic immune cells.
Supplementary Figures S1-S8 from Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts

Ela Elyada,Mohan Bolisetty,Pasquale Laise,William F. Flynn,Elise T. Courtois,Richard A. Burkhart,Jonathan A. Teinor,Pascal Belleau,Giulia Biffi,Matthew S. Lucito,Santhosh Sivajothi,Todd D. Armstrong,Dannielle D. Engle,Kenneth H. Yu,Yuan Hao,Christopher L. Wolfgang,Youngkyu Park,Jonathan Preall,Elizabeth M. Jaffee,Andrea Califano,Paul Robson,David A. Tuveson

DOI: https://doi.org/10.1158/2159-8290.22536710

2023-01-01

Abstract:Supplementary Figure S1 shows the data quality and clustering metrics of the human PDAC single cell transcriptomes, Supplementary Figure S2 shows the distribution of sub-clusters of cells throughout the human dataset, Supplementary Figure S3 shows pathway analysis in human PDAC iCAFs and myCAFs, Supplementary Figure S4 shows the data quality and clustering metrics of the KPC mouse PDAC single cell transcriptomes, Supplementary Figure S5 shows pathway analysis in different KPC CAFs, Supplementary Figure S6 shows that Podoplanin is a pan-fibroblast marker in murine PDAC, Supplementary Figure S7 shows the validation of apCAFs in human PDAC, Supplementary Figure S8 shows the characterization of apCAFs in KPC and orthotopic transplantation models
MUC16 C Terminal-Induced Secretion of Tumor-Derived IL-6 Contributes to Tumor-Associated Treg Enrichment in Pancreatic Cancer

Kun Fan,Chao Yang,Zhiyao Fan,Qiuyi Huang,Yiyin Zhang,He Cheng,Kaizhou Jin,Yu Lu,Zhengshi Wang,Guopei Luo,Xianjun Yu,Chen Liu

DOI: https://doi.org/10.1016/j.canlet.2018.01.017

IF: 9.756

2018-01-01

Cancer Letters

Abstract:Pancreatic cancer is the most lethal tumor. CA125 (gene symbol MUC16) is an important serum marker for pancreatic cancer diagnosis and treatment. High serum CA125 is related to metabolic tumor burden and poor prognosis. The circulating Treg subset is another independent prognostic factor for pancreatic cancer. Our unpublished data indicated that the circulating Treg proportion might be related to the serum CA125 level. However, the potential relationship and underlying mechanism of MUC16 and Treg in pancreatic cancer tissues remain unclear. In this study, we found that pancreatic cancer tissues were positive for both MUC16 C terminal (MUC16c) and Foxp3 expression and that their expression was correlated. MUC16c released into the cytoplasm via EGF induction significantly increased IL-6 expression and secretion. The PI3K/AKT pathway may participate in the regulation of IL-6 expression and secretion. By treating CD4+ T cells with IL-6 or co-culturing the cells with pancreatic cancer cells, tumor-derived IL-6 was identified to promote Foxp3 expression and Treg differentiation, which was significantly inhibited by the JAK2 inhibitor AG-490. In sum, our study demonstrated that the relationship between the MUC16c level and Foxp3 expression in the local tumor environment was consistent with that of the serum CA125 level and circulating Treg proportion in the systemic environment. MUC16c promoted Foxp3 expression and tumor-associated Treg enrichment in tumor tissues through tumor-secreted IL-6 activation of the JAK2/STAT3 pathway. These findings may provide deeper insight into potential pancreatic cancer therapy approaches.

Supplementary Figure 4 from Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma

Supplementary Figure 3 from Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma

Supplementary Figure 2 from Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma

Data from Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma

Supplementary Tables 1-7 from Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma

Supplementary Figures 1-3 from the Novel KLF4/MSI2 Signaling Pathway Regulates Growth and Metastasis of Pancreatic Cancer

Supplementary Figure 5 from Canonical Wnt Signaling is Required for Pancreatic Carcinogenesis

The Clinical Utility of CA125/MUC16 in Pancreatic Cancer: A Consensus of Diagnostic, Prognostic and Predictive Updates by the Chinese Study Group for Pancreatic Cancer (CSPAC)

SUPPLEMENTARY figure 6 from IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma

Abstract A069: Study of MUC16/ERBB axis in pancreatic cancer

SUPPLEMENTARY figure 5 from IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma

Supplementary Figure 2 from Canonical Wnt Signaling is Required for Pancreatic Carcinogenesis

Supplementary Figures 5 - 6 from HAb18G/CD147 Promotes Pstat3-Mediated Pancreatic Cancer Development Via CD44s

Supplementary Figure 4 from HAb18G/CD147 Promotes Pstat3-Mediated Pancreatic Cancer Development Via CD44s

SUPPLEMENTARY figure 7 from IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma

C-terminus of MUC16 Activates Wnt Signaling Pathway Through Its Interaction with Β-Catenin to Promote Tumorigenesis and Metastasis

Supplementary Figure.3 from the Tautomerase Activity of Tumor Exosomal MIF Promotes Pancreatic Cancer Progression by Modulating MDSC Differentiation

Supplementary Figure S1-S18 from A PLCB1–PI3K–AKT Signaling Axis Activates EMT to Promote Cholangiocarcinoma Progression

Supplementary Figure.5 from the Tautomerase Activity of Tumor Exosomal MIF Promotes Pancreatic Cancer Progression by Modulating MDSC Differentiation

Supplementary Figures S1-S8 from Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts

MUC16 C Terminal-Induced Secretion of Tumor-Derived IL-6 Contributes to Tumor-Associated Treg Enrichment in Pancreatic Cancer